Clinical Trial Update: Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 trial is exploring the combination of dalpiciclib with a histone deacetylase inhibitor for HR+/HER2- advanced breast cancer after failure of CDK4/6 in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer Hormone Receptor-positive

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• HDAC inhibitor (histone deacetylase inhibitor)

Snippet

Sponsor: Beijing 302 Hospital | Conditions: HR+/HER2- Advanced Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING